Frontage Labs
“One-Stop Shop” Solution for All Drug Discovery and Development Needs

Across laboratories and research facilities worldwide, the race to develop life-changing drugs and therapies is in full swing. Frontage Labs, a global contract research organization (CRO), stands as a pillar of support to the leading players in the field of drug discovery and development. It offers essential services—from identifying promising drug candidates to navigating the complex web of regulatory requirements—that are pivotal in bringing these innovative treatments from the lab to the market.

The company provides a comprehensive solution for pharmaceutical-based biotech companies, particularly medium-sized companies. It covers all stages of drug development from discovery to early-stage clinical services. Some of the core services areas include chemistry, drug metabolism and pharmacokinetics (DMPK), bioanalytical and preclinical services and expertise in antibody-drug conjugate (ADC) development. These services propel pharmaceutical innovation forward, paving the way for groundbreaking treatments to become a reality.

“We aim to be the one-stop shop for our clients, offering holistic support from drug discovery to clinical trials,” says Dr. John Lin, president at Frontage Labs.

Its services are indispensable to biotech and pharma companies venturing into diverse therapeutic areas to usher in a multitude of drug candidates into the development pipeline. From small molecules and peptides to fusion proteins and biologics drugs including ADC, Frontage plays a crucial role in supporting these advancements.

The emergence of advanced therapeutic agents such as bispecific monoclonal "antibody-drug conjugates, degrader antibody-drug and radioactive drug conjugates, alongside cutting-edge technologies like gene and cell therapy based on cell engineering and gene editing, adds complexity to drug development and approval processes.

Frontage positions itself at the forefront of addressing evolving industry dynamics through a dedication to scientific innovation. It is committed to continuously developing its technical platforms and expertise to support industry trends and provide tailored, financially sustainable solutions to pharmaceutical partners. It provides consulting services and cost-efficient data solutions critical for companies of all sizes.

For its investigational new drug (IND) submission package, Frontage delivers a complete package of integrated services from lead candidate selection (CS) through to the first in human (FIH) Phase 1 studies. Frontage acts as a true drug development partner, offering scientific and regulatory strategic consulting, and conducting all aspects of the required testing leading to preparation and submission of an IND application, FDA interactions, and Phase 1 clinical studies. The program is designed to provide efficient and cost-effective development of new drugs.

Frontage’s extensive expertise, scientific depth and focused solutions are highly regarded by larger pharmaceutical entities. For over fifteen years, it has assisted a company dedicated to treating Alzheimer’s disease in conducting a complex pharmacokinetic study with liquid chromatography-mass spectrometry (LC-MS) technology for a biological monoclonal antibody. This innovative method, validated through standard binding assays, has achieved authorization from the U.S. FDA and China’s National Medical Products Administration (NMPA), highlighting Frontage’s capability to accelerate product development and successfully penetrate major global markets.

We aim to be the one-stop shop for our clients, offering holistic support from drug discovery to clinical trials

Frontage’s comprehensive understanding of its clients’ needs and its expertise in developing tailored scientific solutions are exemplified in a standout case involving a New Jersey biotech company’s toxicity study. Initially, the research encountered substantial hurdles, including constraints posed by limited sample volume and unsuccessful assay development endeavors.

Upon taking the company on as a client, Frontage’s team conducted a comprehensive assessment of the existing assay methodologies. Recognizing the major hurdle of limited sample volume, it promptly devised innovative solutions. Frontage pioneered groundbreaking two-in-one LC-MS methods, transforming the monitoring process for small-molecule toxin and total antibody while significantly reducing sample consumption.

The resulting data proved very promising, facilitating the molecule’s successful transition from the preclinical stage into clinical development.

Strategically located facilities in key pharmaceutical hubs across the globe provide unparalleled access to Frontage’s range of services for worldwide clients. It has a sprawling network spanning North America, Asia Pacific and Europe. This allows it to deliver tailored solutions, foster collaboration and accelerate the development of life-changing therapies on a global scale.

A trusted partner for pharmaceutical and biotech companies, Frontage Labs stands apart as a one-stop shop covering all drug discovery and development needs with its drive to take pharmaceutical innovation forward with its solutions and commitment to excellence.